Adding finerenone to dapagliflozin for kidney protection in diabetes
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding a second medicine (finerenone) to a common diabetes/kidney medicine (dapagliflozin) helps reduce protein in the urine and protect the kidneys better than using dapagliflozin alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years of age or older
- Have type 2 diabetes
- Have protein in your urine (albuminuria)
- Have kidney function in a certain range (eGFR of 25 or higher)
- Be on a stable dose of ACE inhibitor or ARB for at least 4 weeks
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
This trial tests a medication called finerenone to see if it can lower the amount of protein in your urine, which is a sign of kidney damage. It is for people with type 2 diabetes and chronic kidney disease who are already on standard blood pressure medications.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial studies whether a drug called finerenone can safely and effectively treat kidney disease caused by type 2 diabetes. If you qualify, you would take finerenone while your regular diabetes and blood pressure medications continue unchanged.
Hear when a new Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.